Beta-adrenergic antagonists attenuate somatic and aversive signs of opiate withdrawal.
Neuropsychopharmacology
; 9(4): 303-11, 1993 Dec.
Article
em En
| MEDLINE
| ID: mdl-7905738
ABSTRACT
The current studies were designed to evaluate the effectiveness of beta-adrenergic antagonists on opiate withdrawal symptoms utilizing a variety of paradigms. Male Sprague-Dawley rats were made moderately dependent on morphine with daily incremental injections. Both the nonselective beta-antagonist propranolol and the selective beta 1-antagonist atenolol, in the dose range of 5 to 20 mg/kg, were found to significantly reduce many of the somatic responses to either naloxone-precipitated or abstinence-induced withdrawal from morphine. In addition, propranolol (10 mg/kg) significantly reduced a withdrawal-induced conditioned place aversion, while atenolol was effective only at the highest dose tested (20 mg/kg). These data indicate that beta-adrenergic antagonists might be effective in the treatment of opiate addictions.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Abstinência a Substâncias
/
Antagonistas Adrenérgicos beta
/
Entorpecentes
Tipo de estudo:
Diagnostic_studies
Limite:
Animals
Idioma:
En
Revista:
Neuropsychopharmacology
Assunto da revista:
NEUROLOGIA
/
PSICOFARMACOLOGIA
Ano de publicação:
1993
Tipo de documento:
Article